• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    2/14/22 9:50:11 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email
    SC 13G/A 1 brhc10033901_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    SCHEDULE 13G
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

    BeyondSpring Inc.
    (Name of Issuer)

    Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)

    G10830100
    (CUSIP Number)

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d - 1(b)
    ☐ Rule 13d - 1(c)
    ☒ Rule 13d - 1(d)
     


    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G10830100
    13G
    Page 2 of 5 Pages

    1
    NAMES OF REPORTING PERSONS
     
     
    Shenzhen Sangel Capital Management Limited Company
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    People's Republic of China
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    1,066,822(1)
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    187,800(2)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    1,066,822(1)
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    187,800(2)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,254,622(1)(2)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.22%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Includes 693,000 ordinary shares of BeyondSpring Inc., par value $0.0001 per share (“Ordinary Shares”), owned directly by Beijing Sangel Fang Sheng Venture Capital (Limited Partnership), 175,000 Ordinary Shares owned directly by Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership), 124,066 Ordinary Shares owned directly by Shenzhen Sangel Sino-Euro Venture Capital (Limited Partnership) and 74,756 Ordinary Shares owned directly by Sangel Star Biomedical Fund LP. Shenzhen Sangel Capital Management Limited Company (the “Reporting Person”) is the sole general partner of each of Beijing Sangel Fang Sheng Venture Capital (Limited Partnership), Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership), and Shenzhen Sangel Sino-Euro Venture Capital (Limited Partnership), and the Reporting Person is an affiliate of Sangel Star Biomedical Fund LP.

    (2)
    Includes 187,800 Ordinary Shares owned directly by Beijing Huarong Sangel Venture Capital (Limited Partnership) (previously named Beijing Sangel Venture Capital (Limited Partnership)) (“Beijing Huarong Sangel”). The Reporting Person and Huarong Tianze Investments Limited (“Huarong Tianze”) are the general partners of Beijing Huarong Sangel.


    CUSIP No. G10830100
    13G
    Page 3 of 5 Pages

    SCHEDULE 13G

    Item 1(a).
    Name of Issuer: BeyondSpring Inc. (the “Issuer”)
       
    Item 1(b).
    Address of Issuer’s Principal Executive Offices (as reported by the Issuer):
       
     
    28 Liberty Street, 39th Floor
    New York, New York 10005
       
    Item 2(a).
    Name of Person Filing: This Statement on Schedule 13G (this “Statement”) is filed by Shenzhen Sangel Capital Management Limited Company (the “Reporting Person”).
       
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:
       
     
    c/o BeyondSpring Inc.
    28 Liberty Street, 39th Floor
    New York, NY 10005
       
    Item 2(c).
    Citizenship:
     
    People’s Republic of China
       
    Item 2(d).
    Title of Class of Securities:
     
    Ordinary Shares, par value $0.0001 per share (“Ordinary Shares”)
       
    Item 2(e).
    CUSIP Number: G10830100
       
    Item 3.
    If this statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Act;
     
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Act;
     
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Act;
     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940;
     
    (e)
    ☐
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
     
    (j)
    ☐
    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
     
    (k)
    ☐
    Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     
    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ________________________

    Item 4.
    Ownership:

     
    (a)
    Amount beneficially owned: 1,254,622*
         
     
    (b)
    Percent of class: 3.22%
         
     
    (c)
    Number of shares as to which such person has:


    CUSIP No. G10830100
    13G
    Page 4 of 5 Pages

     
    (i)
    Sole power to vote or to direct the vote: 1,066,822
         
     
    (ii)
    Shared power to vote or to direct the vote: 187,800
         
     
    (iii)
    Sole power to dispose or to direct the disposition of: 1,066,822
         
     
    (iv)
    Shared power to dispose or to direct the disposition of: 187,800

     
    * The Ordinary Shares reported above include 693,000 Ordinary Shares owned directly by Beijing Sangel Fang Sheng Venture Capital (Limited Partnership) (“Beijing Sangel”), 175,000 Ordinary Shares owned directly by Shenzhen Sangel Jing Rui Venture Capital (Limited Partnership) (“Shenzhen Sangel Jing”), 124,066 Ordinary Shares owned directly by Shenzhen Sangel Sino-Euro Venture Capital (Limited Partnership) (“Shenzhen Sangel Sino”), and 74,756 Ordinary Shares owned directly by Sangel Star Biomedical Fund LP (“Sangel Star Biomedical”). The Reporting Person is the sole general partner of each of Beijing Sangel, Shenzhen Sangel Jing, and Shenzhen Sangel Sino, and the Reporting Person is an affiliate of Sangel Star Biomedical and, as such, has the ability to direct the management of the business of each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical, including the power to direct decisions regarding the vote and disposition of securities held by each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical; therefore, the Reporting Person may be deemed to have indirect beneficial ownership of the Ordinary Shares held by each of Beijing Sangel, Shenzhen Sangel Jing, Shenzhen Sangel Sino, and Sangel Star Biomedical.

    The Ordinary Shares reported above include 187,800 Ordinary Shares owned directly by Beijing Huarong Sangel Venture Capital (Limited Partnership) (previously named Beijing Sangel Venture Capital (Limited Partnership)) (“Beijing Huarong Sangel”). The Reporting Person and Huarong Tianze Investments Limited (“Huarong Tianze”) are the general partners of Beijing Huarong Sangel and share the ability to direct the management of the business of Beijing Huarong Sangel, including the power to direct decisions regarding the vote and disposition of securities held Beijing Huarong Sangel; therefore, the Reporting Person and Huarong Tianze may each be deemed to have indirect beneficial ownership of the Ordinary Shares held by Beijing Huarong Sangel.
     
    The percentages used in this Schedule 13G/A are calculated based upon the Issuer’s 39,142,253 issued and outstanding Ordinary Shares as of September 30, 2021, as reported by the Issuer in its press release, attached as Exhibit 99.1 to its Form 6-K filed with the U.S. Securities and Exchange Commission on December 30, 2021.

    Item 5.
    Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
       
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    Not Applicable.
       
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable.
       
    Item 8.
    Identification and Classification of Members of the Group: Not Applicable.
       
    Item 9.
    Notice of Dissolution of Group: Not Applicable.
       
    Item 10.
    Certifications:
       
     
    Not Applicable.


    CUSIP No. G10830100
    13G
    Page 5 of 5 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this Statement is true, complete and correct.

    Dated: February 14, 2022

    Shenzhen Sangel Capital Management Limited Company
     
       
    /s/ Mulong Liu
     
    Mulong Liu
    Legal Representative
     



    Get the next $BYSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      11/14/24 9:52:50 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      2/14/24 4:30:59 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      4/7/23 5:02:43 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BeyondSpring downgraded by Jefferies with a new price target

      Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

      12/2/21 5:17:19 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by B of A Securities with a new price target

      B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

      12/2/21 4:49:29 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by William Blair

      William Blair downgraded BeyondSpring from Outperform to Mkt Perform

      12/1/21 10:55:31 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Financials

    Live finance-specific insights

    See more
    • BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

      Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

      3/27/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

      FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), an

      5/3/24 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

      New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC's 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET today. Dial in: 877-407-0792, conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platfor

      11/7/23 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

      FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL. ​​Presentation details are as follows: Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Pli

      5/28/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

      Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Plinabulin has now been administered to more than 7

      5/12/25 4:30:44 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Files 2024 Annual Report on Form 10-K

      FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on March 27, 2025. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Financials & Filings" in the Investors section. The Company will provide

      3/27/25 7:05:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirkby Matthew

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:36 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Huang Lan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:05 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Delaney Brendan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:59:42 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by BeyondSpring Inc.

      10-Q - BeyondSpring Inc. (0001677940) (Filer)

      5/12/25 4:31:17 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BeyondSpring Inc. (0001677940) (Filer)

      5/12/25 4:30:15 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by BeyondSpring Inc.

      10-K - BeyondSpring Inc. (0001677940) (Filer)

      3/27/25 7:06:20 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Leadership Updates

    Live Leadership Updates

    See more
    • SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

      NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

      10/23/23 7:45:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

      Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

      6/20/23 8:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

      SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

      1/17/22 8:50:00 AM ET
      $BYSI
      $CPRX
      $OPNT
      $PALI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)